UK pharma sector stays immune to Brexit as innovation, scale spur deals
Sector being propelled in part by weaker pound and need to keep pipelines supplied with new, lucrative treatments
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
London
AS the United Kingdom's vote to leave the European Union wreaks havoc on the British economy, dealmaking momentum in the country's pharmaceutical industry is showing no signs of letting up.
Healthcare acquisitions in the UK have risen 21 per cent this year as total mergers and acquisitions (M&A) fell 43 per cent in Britain and dropped 16 per cent worldwide, according to data compiled by Bloomberg.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report
